Lung cancer
Today lung cancer offers substantially better survival expectations than it did only a few years ago.
This said, we believe that the multidisciplinary approach, with the different services involved, is the guarantee of being able to offer the best treatment at all times.
Lung cancer is essentially divided into two sub-groups: Small Cell Lung Cancer (SCLC, 15%), and Non-Small Cell Lung Cancer (NSCLC, 85%). SCLC is characterised by its aggressiveness and excellent response to chemotherapy and radiotherapy. However, the responses are not lasting. NSCLC can be subdivided into two sub-groups: Squamous Cell Carcinoma (SCC) and Non-Squamous Cell Carcinoma (NSCC). Both sub-groups must be tested for mutations (EGFR), rearrangements (ALK and ROS1) and, finally, PD-L1 expression levels. The treatment and prognosis will differ substantially depending on the result of the mutations.
information of interest
Call us if you prefer 0034943328000
Treatments for this kind of cancer